X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (112016) 112016
Newsletter (2060) 2060
Newspaper Article (697) 697
Magazine Article (405) 405
Book / eBook (138) 138
Transcript (49) 49
Web Resource (35) 35
Book Chapter (26) 26
Conference Proceeding (26) 26
Dissertation (18) 18
Publication (13) 13
Streaming Video (10) 10
Reference (7) 7
Book Review (6) 6
Report (4) 4
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (103838) 103838
female (59575) 59575
male (50239) 50239
oncology (47367) 47367
middle aged (44421) 44421
antineoplastic agents - adverse effects (41262) 41262
aged (38123) 38123
adult (35299) 35299
cancer (34018) 34018
chemotherapy (31413) 31413
antineoplastic agents - therapeutic use (31208) 31208
treatment outcome (22971) 22971
antineoplastic combined chemotherapy protocols - therapeutic use (20225) 20225
care and treatment (17135) 17135
animals (16515) 16515
antineoplastic agents (15788) 15788
antineoplastic agents - administration & dosage (15737) 15737
antineoplastic combined chemotherapy protocols - adverse effects (14620) 14620
neoplasms - drug therapy (14146) 14146
antimitotic agents (13834) 13834
pharmacology & pharmacy (13223) 13223
aged, 80 and over (12721) 12721
therapy (11908) 11908
research (11468) 11468
medicine & public health (11315) 11315
hematology (11173) 11173
breast neoplasms - drug therapy (10349) 10349
antineoplastic agents - pharmacology (9195) 9195
retrospective studies (8978) 8978
adolescent (8818) 8818
analysis (8516) 8516
health aspects (8504) 8504
drug therapy (8469) 8469
disease-free survival (8187) 8187
prognosis (7931) 7931
risk factors (7914) 7914
breast cancer (7657) 7657
drug administration schedule (7656) 7656
survival (7524) 7524
neoplasm staging (7140) 7140
dose-response relationship, drug (7113) 7113
combined modality therapy (7050) 7050
metastasis (7050) 7050
tumors (7039) 7039
child (7010) 7010
cisplatin (6945) 6945
hematology, oncology and palliative medicine (6945) 6945
lung neoplasms - drug therapy (6910) 6910
clinical trials (6631) 6631
toxicity (6439) 6439
mice (6432) 6432
trial (6324) 6324
survival rate (6007) 6007
time factors (5939) 5939
survival analysis (5913) 5913
antineoplastic combined chemotherapy protocols - administration & dosage (5886) 5886
follow-up studies (5826) 5826
radiotherapy (5696) 5696
apoptosis (5687) 5687
cancer therapies (5415) 5415
clinical trials as topic (5273) 5273
young adult (5248) 5248
patients (5245) 5245
surgery (5190) 5190
cell line, tumor (5098) 5098
carcinoma (5069) 5069
prospective studies (4996) 4996
cisplatin - administration & dosage (4514) 4514
paclitaxel (4468) 4468
neoplasm metastasis (4441) 4441
child, preschool (4405) 4405
carcinoma, non-small-cell lung - drug therapy (4372) 4372
oncology, experimental (4347) 4347
quality of life (4178) 4178
breast neoplasms - pathology (4128) 4128
pharmacology/toxicology (4123) 4123
expression (4087) 4087
phase-ii (4022) 4022
medical research (4010) 4010
disease progression (3996) 3996
complications and side effects (3989) 3989
cancer research (3978) 3978
chemotherapy, adjuvant (3953) 3953
combination (3925) 3925
cisplatin - adverse effects (3903) 3903
deoxycytidine - analogs & derivatives (3892) 3892
medicine, general & internal (3885) 3885
dosage and administration (3847) 3847
drug therapy, combination (3821) 3821
leukemia (3801) 3801
antineoplastic agents - pharmacokinetics (3763) 3763
breast-cancer (3742) 3742
docetaxel (3716) 3716
fluorouracil - administration & dosage (3686) 3686
pharmacokinetics (3611) 3611
doxorubicin (3522) 3522
antibodies, monoclonal - therapeutic use (3493) 3493
efficacy (3481) 3481
internal medicine (3463) 3463
immunotherapy (3450) 3450
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (48) 48
Online Resources - Online (34) 34
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (13) 13
Collection Dvlpm't (Acquisitions) - Vendor file (7) 7
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Chemistry (A D Allen) - Stacks (1) 1
Credit Valley Hospital - Special Collections (1) 1
Dentistry (Harry R Abbott) - Course Reserves (1) 1
Gerstein Science - Circulation Desk (1) 1
Lakeridge Health Sciences - Online (1) 1
Markham Stouffville Hospital - Stacks (1) 1
Scarborough Hospital - Online (1) 1
St. Michael's Hospital - Pharmacy (1) 1
Stacks (1) 1
Sunnybrook Health Sciences Centre - Missing (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Patient Education (1) 1
UofT at Mississauga - Stacks (1) 1
West Park Healthcare Centre - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (109111) 109111
Japanese (2162) 2162
French (1610) 1610
German (1543) 1543
Spanish (527) 527
Chinese (526) 526
Russian (435) 435
Italian (399) 399
Polish (236) 236
Dutch (156) 156
Hungarian (147) 147
Portuguese (137) 137
Czech (132) 132
Danish (123) 123
Norwegian (78) 78
Swedish (72) 72
Finnish (45) 45
Hebrew (36) 36
Croatian (26) 26
Korean (24) 24
Slovak (23) 23
Bulgarian (18) 18
Romanian (16) 16
Serbian (16) 16
Ukrainian (16) 16
Turkish (14) 14
Lithuanian (2) 2
Arabic (1) 1
Icelandic (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the American Academy of Dermatology, ISSN 0190-9622, 2008, Volume 58, Issue 4, pp. 545 - 570
Chemotherapeutic agents give rise to numerous well described adverse effects that may affect the skin, hair, mucous membranes, or nails... 
Dermatology | CELL LUNG-CANCER | CHRONIC MYELOGENOUS LEUKEMIA | GROWTH-FACTOR RECEPTOR | PEGYLATED LIPOSOMAL DOXORUBICIN | PHASE-II TRIAL | RADIATION-RECALL DERMATITIS | CHRONIC LYMPHOCYTIC-LEUKEMIA | TYROSINE-KINASE INHIBITOR | CHRONIC MYELOID-LEUKEMIA | HAND-FOOT SYNDROME | DERMATOLOGY | Erlotinib Hydrochloride | Niacinamide - analogs & derivatives | Drug Eruptions - pathology | Humans | Antibodies, Monoclonal - adverse effects | Phenylurea Compounds | Protein Kinase Inhibitors - adverse effects | Benzenesulfonates - adverse effects | Antibodies, Monoclonal, Humanized | Pyridines - adverse effects | Fusion Proteins, bcr-abl | Antineoplastic Agents - adverse effects | Nail Diseases - chemically induced | Drug-Related Side Effects and Adverse Reactions | Hair Diseases - chemically induced | Pyrroles - adverse effects | Mucous Membrane - drug effects | Cetuximab | Taxoids - adverse effects | Platinum Compounds - adverse effects | Drug Eruptions - etiology | Skin Diseases - chemically induced | Imatinib Mesylate | Piperazines - adverse effects | Antimetabolites - adverse effects | Indoles - adverse effects | Signal Transduction - drug effects | Pyrimidines - adverse effects | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Benzamides | Proteasome Inhibitors | Skin - drug effects | Protein-Tyrosine Kinases - antagonists & inhibitors | Chemotherapy | Platelet-derived growth factor | Formulae, receipts, prescriptions | Dermatologic agents | Lung cancer, Non-small cell | Cancer | Index Medicus
Journal Article
04/2000, Volume 22, Issue 4, 40
Cytostatic antibiotics of the anthracycline class are the best known of the chemotherapeutic agents that cause cardiotoxicity... 
Mitomycin, adverse reactions | Tretinoin, adverse reactions | Etoposide, adverse reactions | Cladribine, adverse reactions | Heart disorders, drug-induced | Pentostatin, adverse reactions | Vinca alkaloids, adverse reactions | Cytostatic antibiotics, adverse reactions | Fluorouracil, adverse reactions | Asparaginase, adverse reactions | Cisplatin, adverse reactions | Carmustine, adverse reactions | Amsacrine, adverse reactions | Ifosfamide, adverse reactions | Mitoxantrone, adverse reactions | Cyclophosphamide, adverse reactions | Cytarabine, adverse reactions | Paclitaxel, adverse reactions | Teniposide, adverse reactions | Antineoplastics, adverse reactions | Busulfan, adverse reactions | Chlormethine, adverse reactions | HEMOLYTIC-UREMIC SYNDROME | SOFT-TISSUE SARCOMAS | HAIRY-CELL LEUKEMIA | PHASE-II TRIAL | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | BONE-MARROW TRANSPLANTATION | HIGH-DOSE CYCLOPHOSPHAMIDE | SOUTHWEST-ONCOLOGY-GROUP | ACUTE LYMPHOBLASTIC-LEUKEMIA | METASTATIC BREAST-CANCER | PHARMACOLOGY & PHARMACY | TOXICOLOGY | CONGESTIVE-HEART-FAILURE | Antineoplastic Agents - adverse effects | Humans | Risk Factors | Antimetabolites, Antineoplastic - adverse effects | Antibiotics, Antineoplastic - adverse effects | Heart Diseases - prevention & control | Antineoplastic Agents, Alkylating - adverse effects | Heart Diseases - chemically induced | Angiogenesis Inhibitors - adverse effects
Book Review
The oncologist (Dayton, Ohio), ISSN 1549-490X, 2017, Volume 22, Issue 7, pp. 823 - 833
...) has become standard of care. These agents are administered until disease progression or unacceptable toxicity occurs... 
BRAF | Mitogen‐activated protein kinase signaling system | Drug‐related side effects and adverse reactions | Protein kinase inhibitors | Melanoma | Mitogen-activated protein kinase signaling system | Drug-related side effects and adverse reactions | IMPROVED SURVIVAL | PHASE-3 | COMBINATION | COMBINED DABRAFENIB | THERAPY | MEK INHIBITION | ONCOLOGY | DOUBLE-BLIND | COBIMETINIB | BRAF-MUTANT MELANOMA | VEMURAFENIB | Oximes - adverse effects | Humans | Fever - therapy | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Carbamates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Fever - chemically induced | Pyridones - administration & dosage | Benzimidazoles - administration & dosage | Antineoplastic Agents - adverse effects | Benzimidazoles - adverse effects | Skin Diseases - chemically induced | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - pathology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Azetidines - administration & dosage | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Piperidines - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Pyrimidinones - administration & dosage | Pyridones - adverse effects | Sulfonamides - administration & dosage | Melanoma and Cutaneous Malignancies
Journal Article
JNCI : Journal of the National Cancer Institute, ISSN 0027-8874, 2012, Volume 104, Issue 2, pp. 93 - 113
.... This has raised challenges in the management of adverse events (AEs) associated with the six targeted agents approved in RCC-sorafenib, sunitinib, pazopanib, bevacizumab... 
TYROSINE KINASE INHIBITORS | CONTROLLED-TRIAL | INTERFERON-ALPHA | SUNITINIB TREATMENT | CANCER-PATIENTS | VENOUS THROMBOEMBOLISM | ONCOLOGY | HEART-FAILURE | DOUBLE-BLIND | EXPANDED ACCESS PROGRAM | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Hypothyroidism - chemically induced | Pneumonia - therapy | Anorexia - therapy | Humans | Drug Eruptions - therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Kidney Neoplasms - metabolism | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Weight Loss - drug effects | Benzenesulfonates - adverse effects | Bevacizumab | TOR Serine-Threonine Kinases - antagonists & inhibitors | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Pneumonia - chemically induced | Pyrroles - adverse effects | Antineoplastic Agents - pharmacology | Carcinoma, Renal Cell - drug therapy | Everolimus | Hypothyroidism - therapy | Wound Healing - drug effects | Molecular Targeted Therapy - methods | Sirolimus - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Sirolimus - analogs & derivatives | Europe | Gastrointestinal Tract - drug effects | Cardiovascular System - drug effects | Evidence-Based Medicine | Carcinoma, Renal Cell - metabolism | Indoles - adverse effects | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Anorexia - chemically induced | Kidney Neoplasms - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Drugs | Complications and side effects | Care and treatment | Adverse and side effects | Carcinoma, Renal cell | Research | Drug therapy | Antineoplastic agents
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 11/2011, Volume 103, Issue 21, pp. 1572 - 1587
Unlike cytotoxic agents that indiscriminately affect rapidly dividing cells, newer antineoplastic agents such as targeted therapies and immunotherapies are associated with thyroid dysfunction... 
TYROSINE KINASE INHIBITORS | DENILEUKIN DIFTITOX | PHASE-II TRIAL | ONCOLOGY | SUNITINIB INDUCES HYPOTHYROIDISM | ALPHA-INTERFERON THERAPY | RECOMBINANT INTERLEUKIN-2 | HIGH-DOSE INTERLEUKIN-2 | THYROXINE-BINDING GLOBULIN | RENAL-CELL CARCINOMA | CHRONIC VIRAL-HEPATITIS | Hypothyroidism - chemically induced | Thyroid Function Tests | Hyperthyroidism - diagnosis | Interleukin-2 - adverse effects | Recombinant Fusion Proteins - adverse effects | Humans | Ipilimumab | Antibodies, Monoclonal - adverse effects | Antineoplastic Agents - administration & dosage | Recombinant Proteins - adverse effects | Tetrahydronaphthalenes - adverse effects | Hyperthyroidism - chemically induced | Thalidomide - analogs & derivatives | Antineoplastic Agents - adverse effects | Diphtheria Toxin - adverse effects | Thyroid Hormones - blood | Anticarcinogenic Agents - adverse effects | Interleukin-2 - analogs & derivatives | Thyroiditis, Autoimmune - chemically induced | Molecular Targeted Therapy - methods | Thyroid Gland - drug effects | Thalidomide - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Hyperthyroidism - blood | Radioimmunotherapy | Hypopituitarism - etiology | Hypothyroidism - diagnosis | Alemtuzumab | Hypothyroidism - etiology | Neoplasms - drug therapy | Iodine Radioisotopes - administration & dosage | Hypopituitarism - complications | Neoplasms - immunology | Hypothyroidism - drug therapy | Quality of Life | Interferon-alpha - adverse effects | Hypothyroidism - blood | Thyroid Gland - metabolism | Antibodies, Neoplasm - adverse effects | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Complications and side effects | Usage | Thyroid diseases | Diagnosis | Antineoplastic agents | Thyroid gland function tests | Risk factors | Index Medicus | Review
Journal Article
Journal Article